TNF and rheumatoid arthritis: Estimates derived from randomized clinical trials suggest that about 40–50% of RA patients treated for at least 6 months with one of the three first-generation TNF inhibitors (i.e., etanercept, adalimumab and infliximab) failed to achieve the ACR50 response criteria [30].